Back

Title
  • en Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
Alternative
  • en Confirmation of the 8th edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
Creator
Accessrights open access
Rights
  • en This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-017-1107-0
Subject
  • Other en AJCC/UICC TNM staging system
  • Other en Head and neck cancer
  • Other en Human papillomavirus
  • Other en Oropharynx
  • Other en p16
  • NDC 490
Description
  • Abstract en Background: Several studies have demonstrated that the 7th edition of the AJCC/UICC TNM staging classification system does not consistently distinguish between prognostic subgroups for human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). The 8th edition of the AJCC/UICC TNM staging came into effect for use with HPV-mediated OPSCC on or after January 1, 2017. This study confirms that the 8th edition of the AJCC/UICC TNM staging system for HPV- mediated OPSCC accurately reflects disease outcomes. Patients and methods:We retrospectively analyzed 195 patients with OPSCC treated at Hokkaido University Hospital, Sapporo, Japan between 1998 and 2015. HPV status was evaluated by immunohistochemical analysis of p16. Results: Of the 195 OPSCC patients, 111 (56.9%) were p16 positive, and 84 (43.1%) were p16 negative. The 3-year overall survival rate (OS) was significantly lower in the p16-negative patients with stage III-IV in comparison with those with stage I-II (55.0% vs 93.1%, p<0.01). The 3-year OS did not differ significantly between stage I-II and stage III-IV in the p16-positive patients (86.7% vs 87.7%). According to the 8th edition of the AJCC/UICC TNM staging system, stage I-II and stage III could be differentiated on the basis of the 3-year OS in the p16-positive patients (90.9% vs 70.2%, p<0.01). Conclusions: The 7th edition of the AJCC/UICC TNM staging system is suitable for use with p16-negative patients; however, it does not effectively discriminate between p16-positive patients. Therefore, the 8th edition of the AJCC/UICC TNM staging system is more suitable for HPV-mediated OPSCC in Japan.
Publisher en Springer
Date
    Issued2017-08
Language
  • eng
Resource Type journal article
Version Type AM
Identifier HDL http://hdl.handle.net/2115/71138
Relation
  • isVersionOf DOI https://doi.org/10.1007/s10147-017-1107-0
  • PMID 28271391
Journal
    • PISSN 1341-9625
      • en International journal of clinical oncology
      • Volume Number22 Issue Number4 Page Start682 Page End689
File
Oaidate 2023-07-26